Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T12:55:27.968Z.
Calculation as of: 2026-10-06T12:55:27.968Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6ac0f7718e38414e938d0d293bbdd3741326646c7ebae4135e2c8e12d98e3a9c
PE RATIO
N/A
Market Cap
$1.03B
PE Ratio
N/A
TTM Avg
50.11
3Y Avg
34.45
5Y Avg
50.26
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aktis Oncology, Inc. (AKTS) | $989.05M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | N/A | 5.99 | 5.99 | 5.99 |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | N/A | 50.11 | 34.45 | 50.26 |
| CeriBell, Inc. (CBLL)vs › | $943.26M | N/A | N/A | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.04B | N/A | 31.31 | 24.04 | 24.04 |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | N/A | N/A | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | 5.98 | 5.80 | 5.80 | 5.80 |
| HealthStream, Inc. (HSTM)vs › | $921.45M | 44.09 | 37.03 | 45.62 | 62.08 |
| Bioventus Inc. (BVS)vs › | $915.95M | 17.55 | 40.25 | 40.25 | 34.02 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | N/A | 43.56 | 43.56 | 43.56 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$18.52
Forward EPS (Est.)
$-1.79
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
